What are the types of secretion systems in Pseudomonas species?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Types of Secretion Systems in Pseudomonas

Pseudomonas species possess five distinct types of secretion systems (Types I, II, III, V, and VI), with Type IV notably absent in most strains, representing one of the most diverse arsenals of protein export machinery among Gram-negative bacteria.

Overview of Secretion System Architecture

Pseudomonas aeruginosa and related species have evolved multiple secretion systems that can be categorized based on their transport mechanisms:

Single-Step Secretion Systems (Cross Both Membranes)

  • Type I Secretion System (T1SS): Transports proteins across both inner and outer membranes in one energy-coupled step 1
  • Type III Secretion System (T3SS): Directly injects effector proteins into host cell cytosol; present in P. aeruginosa but absent in P. fluorescens 1
  • Type VI Secretion System (T6SS): The most recently characterized system; P. aeruginosa encodes three distinct T6SS variants (H1-T6SS, H2-T6SS, and H3-T6SS) 2, 3

Two-Step Secretion Systems

  • Type II Secretion System (T2SS): Proteins first cross the inner membrane via Sec or Tat pathways, then traverse the outer membrane through the main terminal branch (MTB) 1
  • Type V Secretion System (T5SS): Includes autotransporters (AT), two-partner secretion (TPS), and fimbrial usher porin (FUP) families 1

Key Distinguishing Features

Type III Secretion System

  • Functions as a molecular syringe for direct host cell injection
  • Critical virulence factor in P. aeruginosa pathogenicity
  • Absent in plant-associated P. fluorescens, highlighting its role in animal pathogenesis 1

Type VI Secretion System - Special Considerations

P. aeruginosa's three T6SS variants show functional specialization:

  • Hcp (hemolysin-coregulated protein) serves as the hallmark effector protein 3
  • Associated with biofilm formation rather than environmental adaptation 3
  • Genomic analysis reveals five main phylogenetic clusters across Pseudomonas species, with most strains carrying T6SSs from multiple clades 4
  • Expression patterns: hcp1 and hcp3 genes show higher expression in strong biofilm-forming strains 3

Type IV Secretion System - Notable Absence

Type IV is conspicuously absent in both P. aeruginosa PAO1 and P. fluorescens Pf0-1 1, distinguishing Pseudomonas from many other Gram-negative pathogens.

Functional Distribution

The secretion systems serve distinct physiological roles:

  • Environmental adaptation: Types I, II, and V primarily handle enzyme secretion for nutrient acquisition
  • Virulence and pathogenicity: Types III and VI are weaponized for host interaction 2
  • Bacterial competition: Type VI functions in interbacterial warfare and niche establishment 5

Clinical Relevance

The diversity of secretion systems in P. aeruginosa contributes to its status as a formidable nosocomial pathogen 2. These systems collectively enable:

  • Colonization of diverse environments
  • Evasion of host immune responses
  • Establishment of chronic infections
  • Biofilm formation in clinical settings

Common Pitfall

Do not assume all Pseudomonas species possess identical secretion system repertoires. P. fluorescens lacks Type III and IV systems, reflecting its plant-symbiont lifestyle versus P. aeruginosa's opportunistic pathogen profile 1.

Related Questions

A 68-year-old white male, 21 days post total hip arthroplasty, has itching at the clean, dry surgical site without drainage; what measures can be taken to resolve or minimize the itching?
In a 79-year-old patient receiving enteral tube feeding who presents with diarrhea, which stool test should be ordered first?
In a 55‑year‑old man with a recent electrocardiogram showing sinus rhythm, a QS complex in V1, poor R‑wave progression in V2, left‑atrial enlargement, and a prolonged QT interval, what is the most likely diagnosis and appropriate treatment?
How do I convert an infusion rate of 60 cc per hour to drops per minute using a microdrip set?
What is the appropriate evaluation and management for an 82‑year‑old male presenting with lower abdominal pain and a burning sensation on urination?
In a 62-year-old woman with no comorbidities, hemoglobin 6 g/dL, blood‑tinged mucus, prior mildly elevated alkaline phosphatase with normal gamma‑glutamyl transferase, a history of intravenous iron sucrose without post‑infusion hemoglobin checks, and prolonged bleeding from minor wounds, what is the most likely diagnosis?
How is the PEARL score calculated for a patient with chronic obstructive pulmonary disease and how are the resulting risk categories interpreted for 90‑day readmission or death?
What are the clinical manifestations of proctocolitis?
What are the recommended initial and target doses for the standard chronic heart‑failure medications (ACE inhibitor, ARB, ARNI [sacubitril/valsartan], beta‑blocker, mineralocorticoid receptor antagonist, loop diuretic, SGLT2 inhibitor, and adjunct agents) in an average adult without severe renal or hepatic impairment?
What is the recommended treatment for trigger point pain?
What are the recommended intravenous medication dosing regimens for acute decompensated heart failure?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.